文献速递中医内科中药与中成药合理使用

二黄方通过抑制CXCL6/JAK/STAT3信号通路改善糖尿病肾病大鼠肾纤维化

ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway.
PubMed 文献 · Front Pharmacol · 2020-01-24

本研究评估二黄方(EHF)对糖尿病肾病(DN)大鼠肾纤维化的作用及机制。采用高糖高脂饮食联合单次腹腔注射链脲佐菌素(STZ)建立DN大鼠模型,灌胃EHF提取物(4、2、1 g/kg·d-1)8周。结果显示EHF呈剂量依赖性改善生化指标及肾组织病理和纤维化,其作用与抑制CXCL6/JAK/STAT3信号通路相关。

要点

  • EHF可剂量依赖性改善DN大鼠生化指标及肾纤维化。
  • EHF抑制NRK-49F细胞增殖及炎症和纤维化因子表达。
  • EHF抗肾纤维化作用与抑制CXCL6/JAK/STAT3通路相关。

核心结论

  • EHF通过抑制CXCL6/JAK/STAT3信号通路改善DN大鼠肾纤维化,该通路与组织炎症和纤维化相关。

研究设计与样本

  • 采用高糖高脂饮食联合单次腹腔注射STZ建立DN大鼠模型,灌胃EHF提取物(4、2、1 g/kg·d-1)8周。
  • 体外实验使用NRK-49F细胞,通过CCK-8检测EHF对细胞增殖的影响。

主要发现

  • EHF呈剂量依赖性改善DN大鼠异常生化参数(血糖、体重、Scr、BUN、UA、U-Alb、UAE)。
  • EHF减轻肾组织异常组织学改变和纤维化。
  • EHF在体内外均抑制NRK-49F增殖并降低炎症和纤维化相关因子(IL-6、TNF-α、TGF-β1、Collagen I/III、MMP2/9)表达。
  • Collagen I/III、PCNA、MMP2/9和p-STAT3水平与CXCL6呈正相关。

临床怎么用

  • EHF临床用于治疗DN已超过30年,本研究为其改善肾纤维化提供了机制依据。
  • EHF的作用与CXCL6/JAK/STAT3通路相关,提示该通路可能作为DN治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetic nephropathy (DN) is one of the main causes of renal fibrosis and is associated with high morbidity and mortality. Traditional Chinese Medicine (TCM) therapy has a long history of usage in a clinical setting and its usage is increasing. ErHuang Formula (EHF), a Chinese herbal compound, has been clinically used in treating DN for more than 30 years. However, its mechanism of action is still unknown. This study was conducted to evaluate the effect of EHF on renal fibrosis in a DN rat model and explore its underlying mechanism. The DN rat model was established by high-sugar-fat diet combined with a single intraperitoneal injection of streptozotocin (STZ), and EFH extract (4, 2, 1 g/kg d-1) was administered orally for 8 weeks. The biochemical parameters (blood glucose, weight, Scr, BUN, UA, U-Alb and UAE) were analyzed. The pathological changes in renal tissue were observed by histological staining with H&E and Masson. The effect of EHF on the proliferation of NRK-49F cells was examined by CCK-8 assay and the levels of several inflammation and fibrosis related cytokines (IL-6, TNF-α, TGF-β1, Collagen I/III, MMP2/9) in serum and NRK-49F cell culture supernatants were detected by enzyme-linked immunoassay (ELISA). The mRNA levels of CXCL6, CXCR1, Collagen I/III, MMP2/9 in renal tissue were also measured by quantitative RT-PCR. Furthermore, the protein expression of PCNA, Collagen I/III, MMP2/9, CXCL6, CXCR1, p-STAT3, STAT3 in renal tissue and NRK-49F cells were determined by western blot. EHF improved the abnormal biochemical parameters and ameliorated the abnormal histology and fibrosis of renal tissue in a dose-dependent manner. EHF inhibited NRK-49F proliferation and decreased the expressions of inflammation and fibrosis related factors both in vitro and in vivo. Interestingly, the levels of Collagen I/III, PCNA, MMP2/9 and p-STAT3 were positively correlated with CXCL6. The amelioration of renal fibrosis in DN by EHF is related to CXCL6/JAK/STAT3 signal pathway, which is associated with inflammation and fibrosis of the tissue. These findings may have clinical implications for the treatment of DN.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Shen YL, Jiang YP, Li XQ, et al. ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway. Front Pharmacol. 2020. PMID: 32038260. doi:10.3389/fphar.2019.01596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。